Warfarin
What's New
Last Posted: Mar 12, 2024
- Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Benjamin Cross et al. Pharmacogenomics J 2024 3 (2) 7 - Targeted next-generation sequencing of genes involved in Warfarin Pharmacodynamics and pharmacokinetics pathways using the Saudi Warfarin Pharmacogenetic study (SWAP)
M Al Ammari et al, The PGX journal, February 6, 2023 - Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey Eric T et al. The pharmacogenomics journal 2021 10 (1) 69-74 - Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis
S Jiang et al, The PGX journal, April 1, 2022 - Investigating the use of data-driven artificial intelligence in computerised decision support systems for health and social care: A systematic review.
Cresswell Kathrin et al. Health informatics journal 2020 Jan 1460458219900452 - Methodological quality of clinical practice guidelines for genetic testing in children: A systematic assessment using the appraisal of guidelines for research and evaluation II instrument.
Jiao Xue-Feng et al. Medicine 2019 Dec 98(52) e18521 - Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
Ye Zhu, et al. Genetics in Medicine, October 8, 2019 - Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation
W Hernandez et al, The Pharmacogenomics Journal. September 10, 2019 - Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects.
de Oliveira Magalhães Mourão Aline et al. The pharmacogenomics journal 2019 Aug - Precision dosing of warfarin: open questions and strategies
X Li et al, Pharmacogenomics J, February 12, 2019 - Utilizing Whole-Exome Sequencing to Characterize the Phenotypic Variability of Sickle Cell Disease.
Alsultan Abdulrahman et al. Genetic testing and molecular biomarkers 2018 Sep - Genotype-guided Warfarin Dosing in Patients with Mechanical Valves: a Randomized Controlled Trial.
Xu Zhe et al. The Annals of thoracic surgery 2018 Sep - Local Coverage Determination (LCD): Biomarkers Overview (L35062)
The U.S. Centers for Medicare & Medicaid Services - CLINGEN Actionability Report for Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A) - F5
ClinGen Actionability Working Group - CLINGEN Actionability Report for Factor V Leiden, Heterozygous - F5
ClinGen Actionability Working Group - CLINGEN Actionability Report for Cerebral cavernous malformations 1, 2, and 3 - KRIT1, CCM2, PDCD10
ClinGen Actionability Working Group - Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.
Syn Nicholas L et al. BMC medicine 2018 Jul 16(1) 104 - Genotype-guided warfarin therapy: current status.
Tavares Letícia C et al. Pharmacogenomics 2018 Apr - Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.
Wigle Theodore J et al. Journal of personalized medicine 2017 Dec (4) - Precision Medicine: Making Warfarin Safer
NIH Director's blog, Oct 3, 2017
More
About RCH PHGKB
Reproductive and Child Health PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to reproductive and child Health...more
Content Summary
Common RCH Related Topics
- Attention Deficit/Hyperactivity Disorder
- Autism
- Birth Defects
- Carrier Testing
- Cerebral Palsy
- Congenital heart defects
- Pregnancy loss
- Developmental Disabilities
- Gestational Diabetes
- Hearing loss
- Neural tube defects
- Infant Mortality
- Infertility
- Learning disability
- Newborn Screening
- Preeclampsia
- Prematurity
- Prenatal Testing
- Stillbirth
- Sudden Infant Death Syndrome
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: